
|Videos|December 18, 2020
Safety and efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
How European clinicians are revolutionizing retina care
4
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
5











































